Philogen S.p.A. (PHIL.MI)

EUR 21.4

(-0.47%)

Total Liabilities Summary of Philogen S.p.A.

Philogen S.p.A.'s latest annual total liabilities in 2023 was 28.68 Million EUR , up 2.78% from previous year.
Philogen S.p.A.'s latest quarterly total liabilities in 2023 FY was 28.68 Million EUR , up 2.78% from previous quarter.
Philogen S.p.A. reported annual total liabilities of 27.9 Million EUR in 2022, up 0.86% from previous year.
Philogen S.p.A. reported annual total liabilities of 27.66 Million EUR in 2021, down -7.15% from previous year.
Philogen S.p.A. reported quarterly total liabilities of 28.68 Million EUR for 2023 FY, up 2.78% from previous quarter.
Philogen S.p.A. reported quarterly total liabilities of 28.68 Million EUR for 2023 Q3, down -4.56% from previous quarter.

Annual Total Liabilities Chart of Philogen S.p.A. (2023 - 2017)

Historical Annual Total Liabilities of Philogen S.p.A. (2023 - 2017)

Year	Total Liabilities	Total Liabilities Growth
2023	28.68 Million EUR	2.78%
2022	27.9 Million EUR	0.86%
2021	27.66 Million EUR	-7.15%
2020	29.8 Million EUR	8.53%
2019	27.45 Million EUR	-6.03%
2018	29.21 Million EUR	33.93%
2017	21.81 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2023 Q1	30.05 Million EUR	7.69%
2023 FY	28.68 Million EUR	2.78%
2023 Q3	28.68 Million EUR	-4.56%
2023 Q2	30.05 Million EUR	0.0%
2023 Q4	28.68 Million EUR	0.0%
2022 Q3	27.9 Million EUR	-10.51%
2022 FY	27.9 Million EUR	0.86%
2022 Q2	31.18 Million EUR	0.0%
2022 Q1	31.18 Million EUR	12.7%
2022 Q4	27.9 Million EUR	0.0%
2021 FY	27.66 Million EUR	-7.15%
2021 Q4	27.66 Million EUR	0.0%
2021 Q3	27.66 Million EUR	3.26%
2021 Q2	26.79 Million EUR	0.0%
2021 Q1	26.79 Million EUR	-10.09%
2020 Q1	- EUR	-100.0%
2020 FY	29.8 Million EUR	8.53%
2020 Q4	29.8 Million EUR	0.0%
2019 FY	27.45 Million EUR	-6.03%
2019 Q4	27.45 Million EUR	0.0%
2018 FY	29.21 Million EUR	33.93%
2017 FY	21.81 Million EUR	0.0%

Peer Total Liabilities Comparison of Philogen S.p.A.

Name	Total Liabilities	Total Liabilities Difference
ARTERRA BIOSCIENCE	1.8 Million EUR	-1491.276%
Ulisse Biomed S.p.A.	4.69 Million EUR	-510.612%